| Min Pa: | Min Pa(max): | Activity's type: |
| Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |
|---|---|---|---|---|---|---|
| 0.949 | 0.002 | 0.975 | Aldehyde oxidase inhibitor | 0.975 0.001 DBMET01213 0.892 0.003 DBMET00107 0.759 0.005 DBMET00108 0.759 0.005 DBMET01728 | DBMET01213 | |
| 0.777 | 0.014 | 0.832 | Caspase 9 stimulant | 0.832 0.007 DBMET01213 0.447 0.084 DBMET00107 0.69 0.025 DBMET00108 0.69 0.025 DBMET01728 | DBMET01213 | |
| 0.676 | 0.007 | 0.676 | Spasmolytic | 0.675 0.007 DBMET01213 0.499 0.023 DBMET00107 0.619 0.011 DBMET00108 0.619 0.011 DBMET01728 | ||
| 0.569 | 0.004 | 0.569 | 5 Hydroxytryptamine 1F antagonist | 0.347 0.005 DBMET01213 0.269 0.007 DBMET00107 0.343 0.005 DBMET00108 0.343 0.005 DBMET01728 | ||
| 0.556 | 0.005 | 0.595 | Cyclic AMP phosphodiesterase inhibitor | 0.595 0.004 DBMET01213 0.335 0.03 DBMET00107 0.384 0.019 DBMET00108 0.384 0.019 DBMET01728 | DBMET01213 | |
| 0.558 | 0.01 | 0.574 | Vasodilator, coronary | 0.574 0.009 DBMET01213 0.402 0.035 DBMET00107 0.515 0.014 DBMET00108 0.515 0.014 DBMET01728 | DBMET01213 | |
| 0.531 | 0.004 | 0.531 | Anesthetic local | 0.429 0.005 DBMET01213 0.263 0.018 DBMET00107 0.449 0.005 DBMET00108 0.449 0.005 DBMET01728 | ||
| 0.527 | 0.004 | 0.542 | Alpha 2b adrenoreceptor antagonist | 0.447 0.004 DBMET01213 0.273 0.012 DBMET00107 0.542 0.004 DBMET00108 0.542 0.004 DBMET01728 | DBMET01728 | |
| 0.517 | 0.024 | 0.535 | Histamine release inhibitor | 0.535 0.019 DBMET01213 0.411 0.07 DBMET00107 0.453 0.049 DBMET00108 0.453 0.049 DBMET01728 | DBMET01213 | |
| 0.495 | 0.002 | 0.495 | Histamine N-methyltransferase inhibitor | 0.45 0.002 DBMET01213 0.285 0.003 DBMET00107 0.357 0.003 DBMET00108 0.357 0.003 DBMET01728 | ||
| 0.495 | 0.004 | 0.497 | Nav1.3 sodium channel blocker | 0.334 0.007 DBMET01213 0.242 0.015 DBMET00107 0.497 0.004 DBMET00108 0.497 0.004 DBMET01728 | DBMET01728 | |
| 0.489 | 0.005 | 0.489 | Nav1.2 sodium channel blocker | 0.413 0.006 DBMET01213 0.228 0.026 DBMET00107 0.474 0.005 DBMET00108 0.474 0.005 DBMET01728 | ||
| 0.485 | 0.005 | 0.485 | Butyrylcholinesterase inhibitor | 0.366 0.007 DBMET01213 0.228 0.018 DBMET00107 0.349 0.008 DBMET00108 0.349 0.008 DBMET01728 | ||
| 0.471 | 0.003 | 0.471 | Nav1.6 sodium channel blocker | 0.426 0.004 DBMET01213 0.251 0.009 DBMET00107 0.416 0.004 DBMET00108 0.416 0.004 DBMET01728 | ||
| 0.459 | 0.012 | 0.459 | Ca2+/calmodulin-dependent kinase II alpha inhibitor | 0.38 0.026 DBMET01213 0.32 0.051 DBMET00107 0.361 0.032 DBMET00108 0.361 0.032 DBMET01728 | ||
| 0.447 | 0.004 | 0.556 | Histamine H1 receptor antagonist | 0.298 0.007 DBMET01213 0.556 0.004 DBMET00107 0.337 0.005 DBMET00108 0.337 0.005 DBMET01728 | DBMET00107 | |
| 0.457 | 0.015 | 0.491 | Anticonvulsant | 0.343 0.03 DBMET01213 0.491 0.013 DBMET00107 0.403 0.021 DBMET00108 0.403 0.021 DBMET01728 | DBMET00107 | |
| 0.445 | 0.006 | 0.445 | 5 Hydroxytryptamine 2B antagonist | 0.354 0.011 DBMET01213 0.188 0.029 DBMET00107 0.365 0.01 DBMET00108 0.365 0.01 DBMET01728 | ||
| 0.423 | 0.009 | 0.423 | 5 Hydroxytryptamine 2 antagonist | 0.283 0.018 DBMET01213 0.171 0.038 DBMET00107 0.408 0.009 DBMET00108 0.408 0.009 DBMET01728 | ||
| 0.426 | 0.019 | 0.46 | Psychostimulant | 0.359 0.03 DBMET01213 0.423 0.019 DBMET00107 0.46 0.015 DBMET00108 0.46 0.015 DBMET01728 | DBMET01728 | |
| 0.407 | 0.005 | 0.407 | 5 Hydroxytryptamine 2C antagonist | 0.246 0.013 DBMET01213 0.155 0.025 DBMET00107 0.381 0.006 DBMET00108 0.381 0.006 DBMET01728 | ||
| 0.404 | 0.006 | 0.502 | Antihistaminic | 0.176 0.025 DBMET01213 0.502 0.005 DBMET00107 0.345 0.008 DBMET00108 0.345 0.008 DBMET01728 | DBMET00107 | |
| 0.4 | 0.003 | 0.4 | Sphingomyelinase inhibitor | 0.304 0.003 DBMET01213 0.226 0.006 DBMET00107 0.351 0.003 DBMET00108 0.351 0.003 DBMET01728 | ||
| 0.401 | 0.005 | 0.553 | NADPH oxidase inhibitor | 0.553 0.004 DBMET01213 0.123 0.079 DBMET00107 0.281 0.015 DBMET00108 0.281 0.015 DBMET01728 | DBMET01213 | |
| 0.398 | 0.005 | 0.398 | Nav1.1 sodium channel blocker | 0.357 0.005 DBMET01213 0.276 0.01 DBMET00107 0.364 0.005 DBMET00108 0.364 0.005 DBMET01728 | ||
| 0.391 | 0.003 | 0.391 | Photosensitizer | 0.354 0.004 DBMET01213 0.227 0.008 DBMET00107 0.23 0.008 DBMET00108 0.23 0.008 DBMET01728 | ||
| 0.393 | 0.006 | 0.456 | Histamine antagonist | 0.158 0.027 DBMET01213 0.456 0.005 DBMET00107 0.333 0.008 DBMET00108 0.333 0.008 DBMET01728 | DBMET00107 | |
| 0.411 | 0.027 | 0.437 | Cardiotonic | 0.323 0.047 DBMET01213 0.437 0.023 DBMET00107 0.301 0.056 DBMET00108 0.301 0.056 DBMET01728 | DBMET00107 | |
| 0.379 | 0.005 | 0.387 | Alpha 2c adrenoreceptor antagonist | 0.316 0.006 DBMET01213 0.177 0.023 DBMET00107 0.387 0.004 DBMET00108 0.387 0.004 DBMET01728 | DBMET01728 | |
| 0.378 | 0.005 | 0.378 | 5 Hydroxytryptamine 7 antagonist | 0.173 0.015 DBMET01213 0.18 0.015 DBMET00107 0.23 0.009 DBMET00108 0.23 0.009 DBMET01728 | ||
| 0.373 | 0.008 | 0.373 | 5 Hydroxytryptamine 2A antagonist | 0.214 0.018 DBMET01213 0.133 0.033 DBMET00107 0.338 0.009 DBMET00108 0.338 0.009 DBMET01728 | ||
| 0.368 | 0.013 | 0.368 | 5 Hydroxytryptamine antagonist | 0.197 0.035 DBMET01213 0.147 0.051 DBMET00107 0.328 0.016 DBMET00108 0.328 0.016 DBMET01728 | ||
| 0.354 | 0.006 | 0.354 | Calcium channel blocker | 0.238 0.019 DBMET01213 0.329 0.007 DBMET00107 0.274 0.013 DBMET00108 0.274 0.013 DBMET01728 | ||
| 0.356 | 0.009 | 0.356 | DNA intercalator | 0.304 0.011 DBMET01213 0.195 0.027 DBMET00107 0.202 0.025 DBMET00108 0.202 0.025 DBMET01728 | ||
| 0.347 | 0.012 | 0.353 | Alpha adrenoreceptor antagonist | 0.257 0.019 DBMET01213 0.11 0.051 DBMET00107 0.353 0.012 DBMET00108 0.353 0.012 DBMET01728 | DBMET01728 | |
| 0.393 | 0.065 | 0.409 | Calpain 2 inhibitor | 0.288 0.122 DBMET01213 0.409 0.056 DBMET00108 0.409 0.056 DBMET01728 | DBMET01728 | |
| 0.335 | 0.01 | 0.335 | Acetylcholine M1 receptor antagonist | 0.295 0.015 DBMET01213 0.23 0.031 DBMET00107 0.292 0.016 DBMET00108 0.292 0.016 DBMET01728 | ||
| 0.351 | 0.03 | 0.351 | Sigma receptor agonist | 0.288 0.041 DBMET01213 0.236 0.052 DBMET00107 0.243 0.05 DBMET00108 0.243 0.05 DBMET01728 | ||
| 0.333 | 0.012 | 0.361 | Ca2+/calmodulin-dependent kinase II delta inhibitor | 0.213 0.042 DBMET01213 0.113 0.09 DBMET00107 0.361 0.009 DBMET00108 0.361 0.009 DBMET01728 | DBMET01728 | |
| 0.378 | 0.063 | 0.399 | Vasodilator, peripheral | 0.397 0.056 DBMET01213 0.399 0.055 DBMET00107 0.281 0.107 DBMET00108 0.281 0.107 DBMET01728 | DBMET00107 | |
| 0.328 | 0.016 | 0.344 | 5 Hydroxytryptamine 1E antagonist | 0.304 0.027 DBMET01213 0.261 0.062 DBMET00107 0.344 0.011 DBMET00108 0.344 0.011 DBMET01728 | DBMET01728 | |
| 0.337 | 0.026 | 0.337 | Ca2+/calmodulin-dependent kinase II beta inhibitor | 0.232 0.058 DBMET01213 0.307 0.034 DBMET00108 0.307 0.034 DBMET01728 | ||
| 0.339 | 0.028 | 0.339 | Ca2+/calmodulin-dependent kinase II gamma inhibitor | 0.205 0.062 DBMET01213 0.216 0.057 DBMET00108 0.216 0.057 DBMET01728 | ||
| 0.315 | 0.006 | 0.32 | Alpha 2a adrenoreceptor antagonist | 0.292 0.007 DBMET01213 0.121 0.029 DBMET00107 0.32 0.006 DBMET00108 0.32 0.006 DBMET01728 | DBMET01728 | |
| 0.32 | 0.02 | 0.32 | MAP-kinase-activated kinase 5 inhibitor | 0.287 0.038 DBMET01213 0.243 0.064 DBMET00107 0.314 0.023 DBMET00108 0.314 0.023 DBMET01728 | ||
| 0.331 | 0.034 | 0.339 | Ca2+/calmodulin-dependent protein kinase inhibitor | 0.192 0.08 DBMET01213 0.339 0.031 DBMET00108 0.339 0.031 DBMET01728 | DBMET01728 | |
| 0.34 | 0.044 | 0.402 | DNA damaging | 0.295 0.059 DBMET01213 0.402 0.028 DBMET00107 0.308 0.054 DBMET00108 0.308 0.054 DBMET01728 | DBMET00107 | |
| 0.306 | 0.013 | 0.306 | Antiadrenergic | 0.207 0.023 DBMET01213 0.103 0.054 DBMET00107 0.297 0.014 DBMET00108 0.297 0.014 DBMET01728 | ||
| 0.295 | 0.007 | 0.524 | Mediator release inhibitor | 0.438 0.004 DBMET01213 0.524 0.004 DBMET00107 0.238 0.01 DBMET00108 0.238 0.01 DBMET01728 | DBMET00107 | |
| 0.323 | 0.041 | 0.426 | Amyloid beta aggregation inhibitor | 0.426 0.021 DBMET01213 0.228 0.065 DBMET00108 0.228 0.065 DBMET01728 | DBMET01213 | |
| 0.285 | 0.005 | 0.285 | Protein kinase C gamma inhibitor | 0.272 0.005 DBMET01213 0.237 0.008 DBMET00107 0.252 0.006 DBMET00108 0.252 0.006 DBMET01728 | ||
| 0.294 | 0.014 | 0.294 | Adrenaline antagonist | 0.199 0.024 DBMET01213 0.097 0.056 DBMET00107 0.284 0.014 DBMET00108 0.284 0.014 DBMET01728 | ||
| 0.321 | 0.042 | 0.326 | Vasodilator | 0.326 0.04 DBMET01213 0.219 0.09 DBMET00107 0.255 0.066 DBMET00108 0.255 0.066 DBMET01728 | DBMET01213 | |
| 0.322 | 0.046 | 0.336 | Insulysin inhibitor | 0.319 0.048 DBMET01213 0.258 0.089 DBMET00107 0.336 0.039 DBMET00108 0.336 0.039 DBMET01728 | DBMET01728 | |
| 0.282 | 0.006 | 0.309 | Alpha 1d adrenoreceptor antagonist | 0.195 0.01 DBMET01213 0.109 0.021 DBMET00107 0.309 0.005 DBMET00108 0.309 0.005 DBMET01728 | DBMET01728 | |
| 0.281 | 0.006 | 0.377 | Dopamine D1 antagonist | 0.377 0.004 DBMET01213 0.095 0.027 DBMET00107 0.221 0.009 DBMET00108 0.221 0.009 DBMET01728 | DBMET01213 | |
| 0.288 | 0.014 | 0.357 | Toll-Like receptor 9 antagonist | 0.232 0.024 DBMET01213 0.357 0.006 DBMET00107 0.307 0.012 DBMET00108 0.307 0.012 DBMET01728 | DBMET00107 | |
| 0.283 | 0.011 | 0.283 | 5 Hydroxytryptamine 1 antagonist | 0.166 0.021 DBMET01213 0.082 0.046 DBMET00107 0.229 0.014 DBMET00108 0.229 0.014 DBMET01728 | ||
| 0.279 | 0.009 | 0.282 | Alpha 2 adrenoreceptor antagonist | 0.23 0.013 DBMET01213 0.107 0.043 DBMET00107 0.282 0.009 DBMET00108 0.282 0.009 DBMET01728 | DBMET01728 | |
| 0.353 | 0.084 | 0.364 | GABA C receptor rho-3 antagonist | 0.352 0.085 DBMET01213 0.278 0.132 DBMET00107 0.364 0.078 DBMET00108 0.364 0.078 DBMET01728 | DBMET01728 | |
| 0.279 | 0.011 | 0.279 | Acetylcholine muscarinic antagonist | 0.238 0.017 DBMET01213 0.198 0.025 DBMET00107 0.225 0.019 DBMET00108 0.225 0.019 DBMET01728 | ||
| 0.277 | 0.008 | 0.324 | Alpha 1b adrenoreceptor antagonist | 0.218 0.013 DBMET01213 0.114 0.031 DBMET00107 0.324 0.007 DBMET00108 0.324 0.007 DBMET01728 | DBMET01728 | |
| 0.275 | 0.008 | 0.279 | 5 Hydroxytryptamine 3E antagonist | 0.212 0.045 DBMET01213 0.257 0.013 DBMET00107 0.279 0.007 DBMET00108 0.279 0.007 DBMET01728 | DBMET01728 | |
| 0.329 | 0.066 | 0.395 | Caspase 3 stimulant | 0.395 0.046 DBMET01213 0.3 0.079 DBMET00108 0.3 0.079 DBMET01728 | DBMET01213 | |
| 0.27 | 0.008 | 0.332 | Telomerase inhibitor | 0.188 0.015 DBMET01213 0.332 0.005 DBMET00107 0.163 0.018 DBMET00108 0.163 0.018 DBMET01728 | DBMET00107 | |
| 0.275 | 0.016 | 0.275 | Adenylate cyclase inhibitor | 0.275 0.016 DBMET01213 0.132 0.058 DBMET00107 0.226 0.022 DBMET00108 0.226 0.022 DBMET01728 | ||
| 0.26 | 0.005 | 0.26 | Acetylcholine M4 receptor antagonist | 0.116 0.019 DBMET01213 0.14 0.012 DBMET00107 0.153 0.01 DBMET00108 0.153 0.01 DBMET01728 | ||
| 0.268 | 0.013 | 0.273 | Alpha 1 adrenoreceptor antagonist | 0.194 0.022 DBMET01213 0.086 0.049 DBMET00107 0.273 0.013 DBMET00108 0.273 0.013 DBMET01728 | DBMET01728 | |
| 0.259 | 0.004 | 0.323 | Histamine H2 receptor antagonist | 0.154 0.009 DBMET01213 0.153 0.009 DBMET00107 0.323 0.003 DBMET00108 0.323 0.003 DBMET01728 | DBMET01728 | |
| 0.263 | 0.011 | 0.263 | ATPase inhibitor | 0.245 0.015 DBMET01213 0.203 0.035 DBMET00107 0.248 0.014 DBMET00108 0.248 0.014 DBMET01728 | ||
| 0.297 | 0.045 | 0.297 | Ca(v)3.3 blocker | 0.211 0.169 DBMET01213 0.249 0.102 DBMET00107 0.248 0.104 DBMET00108 0.248 0.104 DBMET01728 | ||
| 0.251 | 0.004 | 0.251 | 5 Hydroxytryptamine 5A antagonist | 0.154 0.007 DBMET01213 0.124 0.011 DBMET00107 0.192 0.005 DBMET00108 0.192 0.005 DBMET01728 | ||
| 0.265 | 0.018 | 0.265 | Cholinergic antagonist | 0.212 0.029 DBMET01213 0.164 0.045 DBMET00107 0.229 0.025 DBMET00108 0.229 0.025 DBMET01728 | ||
| 0.251 | 0.006 | 0.251 | 5 Hydroxytryptamine 1B antagonist | 0.12 0.017 DBMET01213 0.092 0.027 DBMET00107 0.203 0.008 DBMET00108 0.203 0.008 DBMET01728 | ||
| 0.249 | 0.007 | 0.281 | Protein kinase C zeta inhibitor | 0.281 0.006 DBMET01213 0.159 0.018 DBMET00107 0.176 0.015 DBMET00108 0.176 0.015 DBMET01728 | DBMET01213 | |
| 0.249 | 0.008 | 0.249 | Calcium antagonist | 0.123 0.033 DBMET01213 0.139 0.026 DBMET00107 0.127 0.032 DBMET00108 0.127 0.032 DBMET01728 | ||
| 0.284 | 0.045 | 0.284 | Ca2+/calmodulin-dependent kinase I alpha inhibitor | 0.2 0.09 DBMET01213 0.191 0.098 DBMET00108 0.191 0.098 DBMET01728 | ||
| 0.243 | 0.004 | 0.259 | Adenylate cyclase stimulant | 0.254 0.004 DBMET01213 0.194 0.017 DBMET00107 0.259 0.004 DBMET00108 0.259 0.004 DBMET01728 | DBMET01728 | |
| 0.246 | 0.011 | 0.246 | 5 Hydroxytryptamine 1A antagonist | 0.16 0.019 DBMET01213 0.074 0.044 DBMET00107 0.193 0.015 DBMET00108 0.193 0.015 DBMET01728 | ||
| 0.238 | 0.004 | 0.238 | Calcium channel L-type blocker | 0.158 0.009 DBMET01213 0.17 0.008 DBMET00107 0.181 0.007 DBMET00108 0.181 0.007 DBMET01728 | ||
| 0.247 | 0.015 | 0.247 | Dopamine antagonist | 0.197 0.019 DBMET01213 0.217 0.017 DBMET00107 0.208 0.018 DBMET00108 0.208 0.018 DBMET01728 | ||
| 0.236 | 0.004 | 0.236 | 5 Hydroxytryptamine 5 antagonist | 0.145 0.008 DBMET01213 0.114 0.013 DBMET00107 0.189 0.005 DBMET00108 0.189 0.005 DBMET01728 | ||
| 0.239 | 0.008 | 0.239 | Protein kinase C mu inhibitor | 0.167 0.019 DBMET01213 0.102 0.055 DBMET00107 0.222 0.009 DBMET00108 0.222 0.009 DBMET01728 | ||
| 0.248 | 0.02 | 0.248 | Acetylcholine antagonist | 0.196 0.032 DBMET01213 0.155 0.048 DBMET00107 0.213 0.028 DBMET00108 0.213 0.028 DBMET01728 | ||
| 0.247 | 0.029 | 0.247 | Cholinergic | 0.22 0.038 DBMET01213 0.177 0.058 DBMET00108 0.177 0.058 DBMET01728 | ||
| 0.236 | 0.024 | 0.237 | Acetylcholinesterase inhibitor | 0.237 0.023 DBMET01213 0.159 0.05 DBMET00108 0.159 0.05 DBMET01728 | DBMET01213 | |
| 0.221 | 0.01 | 0.343 | 5 Hydroxytryptamine uptake inhibitor | 0.092 0.029 DBMET01213 0.105 0.025 DBMET00107 0.343 0.005 DBMET00108 0.343 0.005 DBMET01728 | DBMET01728 | |
| 0.268 | 0.059 | 0.268 | HERG channel blocker | 0.208 0.085 DBMET00107 | ||
| 0.223 | 0.015 | 0.223 | Dopamine D2 antagonist | 0.179 0.019 DBMET01213 0.222 0.015 DBMET00107 0.173 0.019 DBMET00108 0.173 0.019 DBMET01728 | ||
| 0.242 | 0.036 | 0.242 | Protein kinase C nu inhibitor | 0.138 0.077 DBMET01213 0.196 0.048 DBMET00108 0.196 0.048 DBMET01728 | ||
| 0.219 | 0.014 | 0.219 | Calcium channel (voltage-sensitive) blocker | 0.13 0.046 DBMET01213 0.174 0.024 DBMET00107 0.176 0.023 DBMET00108 0.176 0.023 DBMET01728 | ||
| 0.211 | 0.008 | 0.216 | DNA repair enzyme inhibitor | 0.216 0.007 DBMET01213 0.147 0.034 DBMET00107 0.188 0.011 DBMET00108 0.188 0.011 DBMET01728 | DBMET01213 | |
| 0.209 | 0.01 | 0.209 | Dopamine D3 antagonist | 0.136 0.017 DBMET01213 0.087 0.029 DBMET00107 0.18 0.012 DBMET00108 0.18 0.012 DBMET01728 | ||
| 0.213 | 0.015 | 0.227 | Alpha 1a adrenoreceptor antagonist | 0.146 0.024 DBMET01213 0.064 0.054 DBMET00107 0.227 0.014 DBMET00108 0.227 0.014 DBMET01728 | DBMET01728 | |
| 0.201 | 0.015 | 0.201 | MAP3K9 inhibitor | 0.182 0.025 DBMET01213 0.17 0.035 DBMET00107 0.196 0.017 DBMET00108 0.196 0.017 DBMET01728 | ||
| 0.285 | 0.101 | 0.445 | Thyroid hormone antagonist | 0.269 0.112 DBMET01213 0.445 0.044 DBMET00107 | DBMET00107 | |
| 0.259 | 0.075 | 0.259 | Glucose-6-phosphate dehydrogenase-6-phosphogluconolactonase inhibitor | 0.239 0.081 DBMET01213 0.213 0.093 DBMET00108 0.213 0.093 DBMET01728 | ||
| 0.22 | 0.037 | 0.307 | Antipruritic | 0.173 0.071 DBMET01213 0.307 0.013 DBMET00107 0.222 0.036 DBMET00108 0.222 0.036 DBMET01728 | DBMET00107 | |
| 0.187 | 0.005 | 0.187 | Ca2+-transporting ATPase inhibitor | 0.179 0.008 DBMET01213 0.156 0.03 DBMET00107 0.174 0.01 DBMET00108 0.174 0.01 DBMET01728 | ||
| 0.249 | 0.069 | 0.289 | Tyrosine 3 hydroxylase inhibitor | 0.289 0.039 DBMET01213 0.229 0.091 DBMET00107 0.255 0.064 DBMET00108 0.255 0.064 DBMET01728 | DBMET01213 | |
| 0.278 | 0.1 | 0.435 | Thyroid hormone beta antagonist | 0.255 0.115 DBMET01213 0.435 0.044 DBMET00107 | DBMET00107 | |
| 0.186 | 0.008 | 0.186 | 5 Hydroxytryptamine 1D antagonist | 0.083 0.03 DBMET01213 0.107 0.02 DBMET00107 0.145 0.013 DBMET00108 0.145 0.013 DBMET01728 | ||
| 0.182 | 0.005 | 0.182 | Acetylcholine M5 receptor antagonist | 0.127 0.011 DBMET01213 0.095 0.019 DBMET00107 0.142 0.009 DBMET00108 0.142 0.009 DBMET01728 | ||
| 0.179 | 0.004 | 0.179 | Protein kinase C beta inhibitor | 0.164 0.004 DBMET01213 0.123 0.006 DBMET00107 0.151 0.004 DBMET00108 0.151 0.004 DBMET01728 | ||
| 0.216 | 0.04 | 0.216 | Cytidine deaminase inhibitor | 0.126 0.095 DBMET01213 0.126 0.095 DBMET00107 0.187 0.054 DBMET00108 0.187 0.054 DBMET01728 | ||
| 0.178 | 0.005 | 0.178 | Dopamine D5 antagonist | 0.136 0.007 DBMET01213 0.064 0.017 DBMET00107 0.077 0.013 DBMET00108 0.077 0.013 DBMET01728 | ||
| 0.175 | 0.005 | 0.175 | Protein kinase C eta inhibitor | 0.152 0.007 DBMET01213 0.138 0.009 DBMET00107 0.157 0.007 DBMET00108 0.157 0.007 DBMET01728 | ||
| 0.221 | 0.052 | 0.239 | P-glycoprotein inhibitor | 0.203 0.062 DBMET01213 0.239 0.045 DBMET00107 0.191 0.07 DBMET00108 0.191 0.07 DBMET01728 | DBMET00107 | |
| 0.26 | 0.092 | 0.331 | Hypoxia-inducible factor 1 alpha inhibitor | 0.331 0.052 DBMET01213 0.242 0.108 DBMET00108 0.242 0.108 DBMET01728 | DBMET01213 | |
| 0.18 | 0.012 | 0.185 | Heat shock protein 70 antagonist | 0.185 0.01 DBMET01213 0.142 0.066 DBMET00107 0.161 0.026 DBMET00108 0.161 0.026 DBMET01728 | DBMET01213 | |
| 0.194 | 0.03 | 0.312 | MAO A inhibitor | 0.312 0.014 DBMET01213 0.182 0.033 DBMET00107 0.178 0.034 DBMET00108 0.178 0.034 DBMET01728 | DBMET01213 | |
| 0.278 | 0.115 | 0.372 | Calcium channel activator | 0.286 0.106 DBMET01213 0.254 0.143 DBMET00107 0.372 0.037 DBMET00108 0.372 0.037 DBMET01728 | DBMET01728 | |
| 0.171 | 0.015 | 0.19 | Prolactin inhibitor | 0.19 0.01 DBMET01213 0.143 0.025 DBMET00107 0.096 0.059 DBMET00108 0.096 0.059 DBMET01728 | DBMET01213 | |
| 0.191 | 0.035 | 0.26 | Topoisomerase II inhibitor | 0.26 0.023 DBMET01213 0.102 0.084 DBMET00108 0.102 0.084 DBMET01728 | DBMET01213 | |
| 0.235 | 0.08 | 0.256 | Calpain inhibitor | 0.212 0.102 DBMET01213 0.256 0.059 DBMET00108 0.256 0.059 DBMET01728 | DBMET01728 | |
| 0.163 | 0.01 | 0.163 | Acetylcholine M2 receptor antagonist | 0.117 0.017 DBMET01213 0.112 0.018 DBMET00107 0.12 0.016 DBMET00108 0.12 0.016 DBMET01728 | ||
| 0.169 | 0.016 | 0.221 | Nitric-oxide synthase inhibitor | 0.101 0.058 DBMET01213 0.093 0.072 DBMET00107 0.221 0.007 DBMET00108 0.221 0.007 DBMET01728 | DBMET01728 | |
| 0.235 | 0.086 | 0.25 | Ca2+/calmodulin-dependent kinase IV inhibitor | 0.25 0.065 DBMET00108 0.25 0.065 DBMET01728 | DBMET01728 | |
| 0.191 | 0.044 | 0.285 | MAO inhibitor | 0.285 0.022 DBMET01213 0.163 0.055 DBMET00107 0.148 0.061 DBMET00108 0.148 0.061 DBMET01728 | DBMET01213 | |
| 0.226 | 0.079 | 0.226 | Potassium channel (Voltage-sensitive) blocker | 0.174 0.117 DBMET00107 | ||
| 0.165 | 0.019 | 0.165 | Sphingosine 1-phosphate receptor 2 agonist | 0.137 0.035 DBMET01213 0.102 0.096 DBMET00107 0.123 0.05 DBMET00108 0.123 0.05 DBMET01728 | ||
| 0.16 | 0.016 | 0.16 | Dopamine D4 antagonist | 0.108 0.024 DBMET01213 0.099 0.027 DBMET00108 0.099 0.027 DBMET01728 | ||
| 0.152 | 0.01 | 0.152 | Lanosterol 14 alpha demethylase inhibitor | 0.134 0.019 DBMET01213 0.089 0.074 DBMET00107 0.142 0.014 DBMET00108 0.142 0.014 DBMET01728 | ||
| 0.145 | 0.007 | 0.145 | 5 Hydroxytryptamine 6 antagonist | 0.073 0.028 DBMET01213 0.099 0.015 DBMET00107 0.118 0.01 DBMET00108 0.118 0.01 DBMET01728 | ||
| 0.321 | 0.186 | 0.417 | Ca2+/calmodulin-dependent protein kinase kinase A inhibitor | 0.266 0.262 DBMET00107 0.417 0.086 DBMET00108 0.417 0.086 DBMET01728 | DBMET01728 | |
| 0.142 | 0.011 | 0.142 | Interferon agonist | 0.107 0.024 DBMET01213 0.114 0.02 DBMET00107 0.098 0.03 DBMET00108 0.098 0.03 DBMET01728 | ||
| 0.275 | 0.146 | 0.398 | 15-Lipoxygenase inhibitor | 0.398 0.075 DBMET01213 0.26 0.157 DBMET00108 0.26 0.157 DBMET01728 | DBMET01213 | |
| 0.169 | 0.04 | 0.177 | Neuropeptide Y1 antagonist | 0.161 0.05 DBMET01213 0.134 0.093 DBMET00107 0.177 0.033 DBMET00108 0.177 0.033 DBMET01728 | DBMET01728 | |
| 0.23 | 0.105 | 0.267 | Gastrin inhibitor | 0.201 0.148 DBMET00107 0.267 0.061 DBMET00108 0.267 0.061 DBMET01728 | DBMET01728 | |
| 0.144 | 0.02 | 0.153 | Acetylcholine release stimulant | 0.104 0.078 DBMET01213 0.118 0.052 DBMET00107 0.153 0.015 DBMET00108 0.153 0.015 DBMET01728 | DBMET01728 | |
| 0.124 | 0.003 | 0.124 | Adenylate cyclase 1 inhibitor | 0.113 0.004 DBMET01213 0.081 0.008 DBMET00107 0.11 0.004 DBMET00108 0.11 0.004 DBMET01728 | ||
| 0.133 | 0.012 | 0.27 | Adrenaline uptake inhibitor | 0.082 0.026 DBMET01213 0.072 0.032 DBMET00107 0.27 0.005 DBMET00108 0.27 0.005 DBMET01728 | DBMET01728 | |
| 0.157 | 0.039 | 0.211 | Topoisomerase I inhibitor | 0.211 0.024 DBMET01213 0.161 0.037 DBMET00107 | DBMET01213 | |
| 0.223 | 0.112 | 0.223 | 5 Hydroxytryptamine uptake stimulant | 0.202 0.148 DBMET01213 0.222 0.114 DBMET00108 0.222 0.114 DBMET01728 | ||
| 0.136 | 0.025 | 0.143 | Acetylcholine nicotinic antagonist | 0.09 0.046 DBMET01213 0.143 0.022 DBMET00108 0.143 0.022 DBMET01728 | DBMET01728 | |
| 0.191 | 0.08 | 0.191 | Anesthetic general | 0.176 0.09 DBMET01213 | ||
| 0.123 | 0.014 | 0.123 | Dopamine uptake inhibitor | 0.078 0.026 DBMET01213 0.07 0.03 DBMET00107 0.121 0.014 DBMET00108 0.121 0.014 DBMET01728 | ||
| 0.119 | 0.014 | 0.119 | Sigma receptor antagonist | 0.063 0.026 DBMET01213 0.065 0.025 DBMET00107 0.063 0.026 DBMET00108 0.063 0.026 DBMET01728 | ||
| 0.188 | 0.084 | 0.213 | Glyceraldehyde-3-phosphate dehydrogenase inhibitor | 0.213 0.062 DBMET01213 | DBMET01213 | |
| 0.143 | 0.04 | 0.143 | Falcipain 3 inhibitor | 0.106 0.065 DBMET01213 0.1 0.07 DBMET00107 0.099 0.071 DBMET00108 0.099 0.071 DBMET01728 | ||
| 0.122 | 0.02 | 0.135 | Glutamate release inhibitor | 0.123 0.02 DBMET01213 0.135 0.014 DBMET00108 0.135 0.014 DBMET01728 | DBMET01728 | |
| 0.105 | 0.004 | 0.105 | ATM kinase inhibitor | 0.067 0.004 DBMET01213 0.046 0.011 DBMET00107 0.074 0.004 DBMET00108 0.074 0.004 DBMET01728 | ||
| 0.199 | 0.1 | 0.307 | Antiamyloidogenic | 0.307 0.049 DBMET01213 0.212 0.091 DBMET00108 0.212 0.091 DBMET01728 | DBMET01213 | |
| 0.109 | 0.012 | 0.134 | Beta 3 adrenoreceptor antagonist | 0.134 0.008 DBMET01213 0.072 0.031 DBMET00107 0.114 0.011 DBMET00108 0.114 0.011 DBMET01728 | DBMET01213 | |
| 0.104 | 0.012 | 0.104 | Protein kinase C epsilon inhibitor | 0.063 0.028 DBMET01213 0.063 0.029 DBMET00107 0.087 0.016 DBMET00108 0.087 0.016 DBMET01728 | ||
| 0.116 | 0.024 | 0.116 | Hematopoietic | 0.1 0.036 DBMET01213 0.097 0.039 DBMET00107 0.111 0.027 DBMET00108 0.111 0.027 DBMET01728 | ||
| 0.108 | 0.016 | 0.108 | Acetylcholine M3 receptor antagonist | 0.106 0.017 DBMET01213 0.055 0.047 DBMET00107 0.088 0.022 DBMET00108 0.088 0.022 DBMET01728 | ||
| 0.137 | 0.046 | 0.137 | Calcium channel N-type blocker | 0.128 0.054 DBMET00107 0.127 0.055 DBMET00108 0.127 0.055 DBMET01728 | ||
| 0.132 | 0.042 | 0.132 | GABA C receptor antagonist | 0.111 0.063 DBMET01213 0.118 0.055 DBMET00107 0.111 0.062 DBMET00108 0.111 0.062 DBMET01728 | ||
| 0.123 | 0.033 | 0.144 | Alcohol dehydrogenase inhibitor | 0.144 0.022 DBMET01213 0.104 0.048 DBMET00107 0.104 0.048 DBMET00108 0.104 0.048 DBMET01728 | DBMET01213 | |
| 0.1 | 0.012 | 0.1 | Interferon inducer | 0.077 0.026 DBMET01213 0.084 0.021 DBMET00107 0.079 0.025 DBMET00108 0.079 0.025 DBMET01728 | ||
| 0.149 | 0.062 | 0.179 | Sphingosine 1-phosphate receptor 5 antagonist | 0.15 0.061 DBMET01213 0.179 0.024 DBMET00107 0.132 0.095 DBMET00108 0.132 0.095 DBMET01728 | DBMET00107 | |
| 0.102 | 0.016 | 0.102 | Acyl-CoA dehydrogenase inhibitor | 0.058 0.034 DBMET01213 0.064 0.03 DBMET00107 0.059 0.034 DBMET00108 0.059 0.034 DBMET01728 | ||
| 0.106 | 0.02 | 0.106 | Protein kinase C alpha inhibitor | 0.072 0.042 DBMET01213 0.073 0.041 DBMET00107 0.082 0.033 DBMET00108 0.082 0.033 DBMET01728 | ||
| 0.1 | 0.015 | 0.1 | 5 Hydroxytryptamine 3 agonist | 0.067 0.038 DBMET01213 0.082 0.025 DBMET00108 0.082 0.025 DBMET01728 | ||
| 0.115 | 0.032 | 0.115 | Neuropeptide Y antagonist | 0.109 0.035 DBMET00108 0.109 0.035 DBMET01728 | ||
| 0.144 | 0.06 | 0.205 | Toll-Like receptor antagonist | 0.131 0.071 DBMET01213 0.205 0.029 DBMET00107 0.137 0.065 DBMET00108 0.137 0.065 DBMET01728 | DBMET00107 | |
| 0.092 | 0.009 | 0.092 | Kinesin-like protein 1 inhibitor | 0.067 0.013 DBMET01213 0.033 0.032 DBMET00108 0.033 0.032 DBMET01728 | ||
| 0.092 | 0.009 | 0.092 | Kinesin antagonist | 0.067 0.013 DBMET01213 0.033 0.032 DBMET00108 0.033 0.032 DBMET01728 | ||
| 0.102 | 0.02 | 0.105 | CC chemokine 5 receptor agonist | 0.105 0.017 DBMET01213 0.087 0.043 DBMET00107 0.088 0.041 DBMET00108 0.088 0.041 DBMET01728 | DBMET01213 | |
| 0.089 | 0.01 | 0.103 | Myc inhibitor | 0.068 0.021 DBMET01213 0.103 0.007 DBMET00108 0.103 0.007 DBMET01728 | DBMET01728 | |
| 0.083 | 0.005 | 0.083 | Sigma 2 receptor antagonist | 0.061 0.008 DBMET01213 0.066 0.007 DBMET00107 0.055 0.009 DBMET00108 0.055 0.009 DBMET01728 | ||
| 0.108 | 0.032 | 0.136 | Acetylcholine nicotinic agonist | 0.136 0.021 DBMET00108 0.136 0.021 DBMET01728 | DBMET01728 | |
| 0.081 | 0.005 | 0.089 | Benzodiazepine antagonist | 0.051 0.024 DBMET01213 0.089 0.004 DBMET00107 0.058 0.015 DBMET00108 0.058 0.015 DBMET01728 | DBMET00107 | |
| 0.16 | 0.084 | 0.176 | Dual specificity phosphatase inhibitor | 0.176 0.07 DBMET01213 | DBMET01213 | |
| 0.224 | 0.149 | 0.24 | Antithrombotic | 0.207 0.169 DBMET01213 0.232 0.142 DBMET00107 0.24 0.134 DBMET00108 0.24 0.134 DBMET01728 | DBMET01728 | |
| 0.11 | 0.036 | 0.11 | Polo-like kinase-1 inhibitor | 0.096 0.051 DBMET01213 0.099 0.046 DBMET00108 0.099 0.046 DBMET01728 | ||
| 0.084 | 0.011 | 0.084 | 5 Hydroxytryptamine 4 antagonist | 0.052 0.035 DBMET01213 0.059 0.024 DBMET00107 0.083 0.012 DBMET00108 0.083 0.012 DBMET01728 | ||
| 0.124 | 0.052 | 0.128 | Transcription factor STAT6 inhibitor | 0.12 0.06 DBMET01213 0.128 0.048 DBMET00108 0.128 0.048 DBMET01728 | DBMET01728 | |
| 0.083 | 0.012 | 0.094 | Topoisomerase II beta inhibitor | 0.094 0.01 DBMET01213 0.045 0.041 DBMET00108 0.045 0.041 DBMET01728 | DBMET01213 | |
| 0.11 | 0.041 | 0.11 | Acetylcholine agonist | 0.101 0.046 DBMET00108 0.101 0.046 DBMET01728 | ||
| 0.218 | 0.149 | 0.304 | Cholesterol antagonist | 0.304 0.089 DBMET01213 | DBMET01213 | |
| 0.098 | 0.03 | 0.098 | Caspase 7 inhibitor | 0.091 0.04 DBMET00108 0.091 0.04 DBMET01728 | ||
| 0.087 | 0.022 | 0.087 | Potassium channel (ATP-sensitive) blocker | 0.085 0.024 DBMET01213 0.072 0.038 DBMET00107 0.073 0.036 DBMET00108 0.073 0.036 DBMET01728 | ||
| 0.086 | 0.022 | 0.086 | 5 Hydroxytryptamine 3 antagonist | 0.059 0.037 DBMET00108 0.059 0.037 DBMET01728 | ||
| 0.271 | 0.211 | 0.308 | MAP kinase 1 inhibitor | 0.308 0.171 DBMET00108 0.308 0.171 DBMET01728 | DBMET01728 | |
| 0.142 | 0.083 | 0.142 | Diuretic | 0.12 0.105 DBMET01213 0.138 0.088 DBMET00108 0.138 0.088 DBMET01728 | ||
| 0.085 | 0.028 | 0.104 | Phospholipase D inhibitor | 0.069 0.055 DBMET01213 0.104 0.012 DBMET00108 0.104 0.012 DBMET01728 | DBMET01728 | |
| 0.073 | 0.016 | 0.073 | Bcl-xL inhibitor | 0.065 0.029 DBMET01213 0.066 0.026 DBMET00107 | ||
| 0.188 | 0.131 | 0.217 | Superoxide dismutase inhibitor | 0.204 0.113 DBMET01213 0.217 0.1 DBMET00108 0.217 0.1 DBMET01728 | DBMET01728 | |
| 0.062 | 0.005 | 0.1 | Benzodiazepine receptor peripheral-type antagonist | 0.041 0.013 DBMET01213 0.1 0.003 DBMET00107 0.036 0.02 DBMET00108 0.036 0.02 DBMET01728 | DBMET00107 | |
| 0.084 | 0.027 | 0.084 | 5 Hydroxytryptamine 3A antagonist | 0.074 0.037 DBMET00108 0.074 0.037 DBMET01728 | ||
| 0.119 | 0.063 | 0.146 | Interleukin 8 antagonist | 0.114 0.07 DBMET01213 0.146 0.037 DBMET00108 0.146 0.037 DBMET01728 | DBMET01728 | |
| 0.06 | 0.004 | 0.06 | Myristoyl transferase inhibitor | 0.025 0.023 DBMET01213 0.03 0.013 DBMET00107 0.059 0.004 DBMET00108 0.059 0.004 DBMET01728 | ||
| 0.092 | 0.037 | 0.113 | Estrogen-related receptor beta agonist | 0.113 0.014 DBMET01213 0.08 0.067 DBMET00107 | DBMET01213 | |
| 0.074 | 0.021 | 0.074 | Nicotinic alpha7 receptor agonist | 0.065 0.027 DBMET00108 0.065 0.027 DBMET01728 | ||
| 0.133 | 0.081 | 0.202 | Lipid peroxidase inhibitor | 0.202 0.041 DBMET01213 | DBMET01213 | |
| 0.102 | 0.051 | 0.102 | Protein kinase C delta inhibitor | 0.08 0.077 DBMET01213 0.086 0.067 DBMET00108 0.086 0.067 DBMET01728 | ||
| 0.149 | 0.099 | 0.149 | LIM domain kinase 1 inhibitor | |||
| 0.066 | 0.016 | 0.066 | Squalene epoxidase inhibitor | 0.061 0.019 DBMET01213 0.059 0.022 DBMET00107 0.055 0.026 DBMET00108 0.055 0.026 DBMET01728 | ||
| 0.185 | 0.135 | 0.373 | 5 Hydroxytryptamine release stimulant | 0.165 0.159 DBMET01213 0.199 0.122 DBMET00107 0.373 0.051 DBMET00108 0.373 0.051 DBMET01728 | DBMET01728 | |
| 0.107 | 0.057 | 0.107 | Gastric antisecretory | 0.093 0.075 DBMET00107 0.107 0.057 DBMET00108 0.107 0.057 DBMET01728 | ||
| 0.059 | 0.009 | 0.074 | Histamine H1 receptor agonist | 0.05 0.018 DBMET00107 0.074 0.004 DBMET00108 0.074 0.004 DBMET01728 | DBMET01728 | |
| 0.099 | 0.05 | 0.099 | Alpha 2d adrenoreceptor antagonist | 0.092 0.065 DBMET00108 0.092 0.065 DBMET01728 | ||
| 0.167 | 0.119 | 0.223 | Potassium channel blocker | 0.223 0.079 DBMET00107 | DBMET00107 | |
| 0.074 | 0.027 | 0.074 | 5 Hydroxytryptamine 1 agonist | 0.069 0.029 DBMET00108 0.069 0.029 DBMET01728 | ||
| 0.053 | 0.009 | 0.088 | Endothelial nitric-oxide synthase inhibitor | 0.088 0.005 DBMET00108 0.088 0.005 DBMET01728 | DBMET01728 | |
| 0.081 | 0.038 | 0.096 | Vanilloid 4 agonist | 0.096 0.02 DBMET00108 0.096 0.02 DBMET01728 | DBMET01728 | |
| 0.056 | 0.012 | 0.056 | 5 Hydroxytryptamine 3B antagonist | 0.041 0.02 DBMET00108 0.041 0.02 DBMET01728 | ||
| 0.187 | 0.145 | 0.187 | Neuropeptide Y2 antagonist | |||
| 0.087 | 0.046 | 0.087 | Glycine receptor antagonist | |||
| 0.16 | 0.12 | 0.161 | Insulin sensitizer | 0.161 0.119 DBMET01213 | DBMET01213 | |
| 0.068 | 0.028 | 0.068 | Potassium channel intermediate-conductance Ca-activated blocker | |||
| 0.069 | 0.029 | 0.096 | Histone deacetylase SIRT3 inhibitor | 0.064 0.038 DBMET01213 0.096 0.011 DBMET00108 0.096 0.011 DBMET01728 | DBMET01728 | |
| 0.135 | 0.096 | 0.171 | GABA C receptor rho-2 antagonist | 0.171 0.05 DBMET00108 0.171 0.05 DBMET01728 | DBMET01728 | |
| 0.063 | 0.024 | 0.074 | 5 Hydroxytryptamine 1B agonist | 0.074 0.015 DBMET00108 0.074 0.015 DBMET01728 | DBMET01728 | |
| 0.098 | 0.06 | 0.159 | MAO B inhibitor | 0.159 0.034 DBMET01213 | DBMET01213 | |
| 0.067 | 0.029 | 0.067 | Prolactin release inhibitor | 0.065 0.035 DBMET01213 0.06 0.051 DBMET00107 | ||
| 0.048 | 0.011 | 0.048 | 5 Hydroxytryptamine 1D agonist | 0.026 0.023 DBMET00107 0.04 0.014 DBMET00108 0.04 0.014 DBMET01728 | ||
| 0.044 | 0.008 | 0.044 | Urotensin II agonist | 0.036 0.011 DBMET01213 0.033 0.013 DBMET00107 | ||
| 0.054 | 0.018 | 0.054 | Geranyltranstransferase inhibitor | 0.047 0.026 DBMET01213 0.041 0.035 DBMET00108 0.041 0.035 DBMET01728 | ||
| 0.047 | 0.011 | 0.047 | Sigma 1 receptor antagonist | 0.038 0.013 DBMET00107 0.027 0.019 DBMET00108 0.027 0.019 DBMET01728 | ||
| 0.066 | 0.032 | 0.066 | Potassium channel (Ca-activated) blocker | |||
| 0.068 | 0.034 | 0.07 | Protein kinase C iota inhibitor | 0.07 0.032 DBMET00108 0.07 0.032 DBMET01728 | DBMET01728 | |
| 0.188 | 0.155 | 0.188 | Transcription factor STAT inhibitor | 0.183 0.163 DBMET00108 0.183 0.163 DBMET01728 | ||
| 0.074 | 0.041 | 0.083 | Dopamine agonist | 0.083 0.035 DBMET01213 0.081 0.036 DBMET00108 0.081 0.036 DBMET01728 | DBMET01213 | |
| 0.041 | 0.008 | 0.041 | Protein kinase C beta I inhibitor | 0.039 0.01 DBMET01213 0.035 0.017 DBMET00107 0.037 0.013 DBMET00108 0.037 0.013 DBMET01728 | ||
| 0.063 | 0.031 | 0.063 | Acetylcholine muscarinic agonist | |||
| 0.046 | 0.014 | 0.046 | 2,3-Oxidosqualene-lanosterol cyclase inhibitor | 0.04 0.021 DBMET01213 0.041 0.02 DBMET00107 | ||
| 0.099 | 0.068 | 0.099 | Adenylate kinase inhibitor | 0.096 0.074 DBMET00108 0.096 0.074 DBMET01728 | ||
| 0.074 | 0.044 | 0.085 | 5 Hydroxytryptamine agonist | 0.085 0.039 DBMET00108 0.085 0.039 DBMET01728 | DBMET01728 | |
| 0.099 | 0.069 | 0.144 | Carbonic anhydrase XV inhibitor | 0.144 0.033 DBMET01213 | DBMET01213 | |
| 0.151 | 0.121 | 0.151 | MAP kinase kinase 2 inhibitor | 0.142 0.129 DBMET00108 0.142 0.129 DBMET01728 | ||
| 0.036 | 0.007 | 0.046 | Estrogen-related receptor gamma antagonist | 0.046 0.004 DBMET01213 0.033 0.011 DBMET00107 0.027 0.024 DBMET00108 0.027 0.024 DBMET01728 | DBMET01213 | |
| 0.042 | 0.013 | 0.042 | Peptide deformylase inhibitor | 0.029 0.022 DBMET00107 0.035 0.017 DBMET00108 0.035 0.017 DBMET01728 | ||
| 0.047 | 0.018 | 0.047 | GABA uptake inhibitor | 0.047 0.018 DBMET00107 | ||
| 0.052 | 0.025 | 0.056 | CC chemokine 4 receptor antagonist | 0.056 0.019 DBMET00107 0.049 0.029 DBMET00108 0.049 0.029 DBMET01728 | DBMET00107 | |
| 0.039 | 0.012 | 0.039 | Protein kinase C beta II inhibitor | 0.037 0.014 DBMET01213 0.032 0.023 DBMET00107 | ||
| 0.036 | 0.01 | 0.036 | 5 Hydroxytryptamine 6 agonist | 0.027 0.024 DBMET00107 | ||
| 0.118 | 0.092 | 0.118 | Cytokine production inhibitor | |||
| 0.065 | 0.039 | 0.067 | NMDA 2C receptor antagonist | 0.067 0.036 DBMET01213 | DBMET01213 | |
| 0.054 | 0.029 | 0.084 | Dopamine transporter inhibitor | 0.084 0.015 DBMET00108 0.084 0.015 DBMET01728 | DBMET01728 | |
| 0.061 | 0.035 | 0.075 | Nicotinic neuronal receptor agonist | 0.075 0.024 DBMET00108 0.075 0.024 DBMET01728 | DBMET01728 | |
| 0.101 | 0.075 | 0.135 | 5 Hydroxytryptamine 3A agonist | 0.135 0.044 DBMET00108 0.135 0.044 DBMET01728 | DBMET01728 | |
| 0.057 | 0.032 | 0.057 | Neuropeptide Y5 antagonist | |||
| 0.053 | 0.029 | 0.053 | Sodium/calcium exchanger inhibitor | |||
| 0.151 | 0.129 | 0.151 | Focal adhesion kinase 2 inhibitor | |||
| 0.094 | 0.073 | 0.094 | GABA C receptor agonist | 0.089 0.08 DBMET00108 0.089 0.08 DBMET01728 | ||
| 0.057 | 0.035 | 0.063 | Glucosylceramidase inhibitor | 0.063 0.028 DBMET00108 0.063 0.028 DBMET01728 | DBMET01728 | |
| 0.048 | 0.027 | 0.048 | Acetylcholine M1 receptor agonist | |||
| 0.073 | 0.054 | 0.073 | Potassium channel (Tandem pore domain) blocker | 0.071 0.061 DBMET00108 0.071 0.061 DBMET01728 | ||
| 0.09 | 0.071 | 0.107 | Interleukin 1 beta converting enzyme inhibitor | 0.107 0.049 DBMET00108 0.107 0.049 DBMET01728 | DBMET01728 | |
| 0.042 | 0.024 | 0.042 | Leukotriene A4 hydrolase inhibitor | |||
| 0.073 | 0.055 | 0.075 | CYP2A6 inhibitor | 0.075 0.053 DBMET00108 0.075 0.053 DBMET01728 | DBMET01728 | |
| 0.082 | 0.064 | 0.084 | Myeloperoxidase inhibitor | 0.081 0.066 DBMET01213 0.084 0.058 DBMET00108 0.084 0.058 DBMET01728 | DBMET01728 | |
| 0.106 | 0.088 | 0.128 | Aldehyde dehydrogenase inhibitor | 0.128 0.063 DBMET01213 0.117 0.074 DBMET00108 0.117 0.074 DBMET01728 | DBMET01213 | |
| 0.072 | 0.055 | 0.072 | S-adenosyl-L-methionine decarboxylase inhibitor | |||
| 0.049 | 0.032 | 0.055 | Histamine H4 receptor antagonist | 0.055 0.024 DBMET00108 0.055 0.024 DBMET01728 | DBMET01728 | |
| 0.137 | 0.12 | 0.138 | DNA methyltransferase I inhibitor | 0.138 0.118 DBMET01213 | DBMET01213 | |
| 0.044 | 0.028 | 0.063 | Histamine H2 receptor agonist | 0.038 0.037 DBMET00107 0.063 0.013 DBMET00108 0.063 0.013 DBMET01728 | DBMET01728 | |
| 0.091 | 0.075 | 0.091 | Insulin receptor antagonist | |||
| 0.054 | 0.038 | 0.065 | Thromboxane synthase inhibitor | 0.055 0.036 DBMET01213 0.065 0.022 DBMET00108 0.065 0.022 DBMET01728 | DBMET01728 | |
| 0.034 | 0.018 | 0.034 | Acetylcholine M4 receptor agonist | |||
| 0.116 | 0.1 | 0.158 | CDC-like kinase 1 inhibitor | 0.158 0.064 DBMET01213 | DBMET01213 | |
| 0.065 | 0.05 | 0.118 | Alpha adrenoreceptor agonist | 0.118 0.022 DBMET00108 0.118 0.022 DBMET01728 | DBMET01728 | |
| 0.079 | 0.064 | 0.087 | GABA A receptor agonist | 0.087 0.052 DBMET00107 0.077 0.069 DBMET00108 0.077 0.069 DBMET01728 | DBMET00107 | |
| 0.043 | 0.03 | 0.043 | Heme oxygenase inhibitor | |||
| 0.082 | 0.07 | 0.082 | NADH dehydrogenase inhibitor | |||
| 0.063 | 0.051 | 0.083 | Beta adrenoreceptor antagonist | 0.083 0.025 DBMET01213 0.076 0.03 DBMET00108 0.076 0.03 DBMET01728 | DBMET01213 | |
| 0.101 | 0.089 | 0.105 | Beta amyloid protein antagonist | 0.105 0.083 DBMET00108 0.105 0.083 DBMET01728 | DBMET01728 | |
| 0.048 | 0.037 | 0.048 | Dopamine D4 agonist | 0.047 0.04 DBMET00108 0.047 0.04 DBMET01728 | ||
| 0.05 | 0.04 | 0.07 | Histamine agonist | 0.07 0.019 DBMET00108 0.07 0.019 DBMET01728 | DBMET01728 | |
| 0.099 | 0.089 | 0.158 | Alkylator | 0.1 0.089 DBMET01213 0.158 0.042 DBMET00107 0.099 0.089 DBMET00108 0.099 0.089 DBMET01728 | DBMET00107 | |
| 0.094 | 0.084 | 0.111 | GABA receptor agonist | 0.111 0.065 DBMET00107 | DBMET00107 | |
| 0.066 | 0.056 | 0.076 | CXC chemokine receptor antagonist | 0.076 0.042 DBMET00107 | DBMET00107 | |
| 0.049 | 0.039 | 0.055 | 5 Hydroxytryptamine 2 agonist | 0.055 0.032 DBMET00108 0.055 0.032 DBMET01728 | DBMET01728 | |
| 0.109 | 0.101 | 0.133 | Antibacterial (Helicobacter pylori) | 0.133 0.063 DBMET00108 0.133 0.063 DBMET01728 | DBMET01728 | |
| 0.039 | 0.031 | 0.039 | Glutamate (mGluR1a) antagonist | 0.038 0.033 DBMET00108 0.038 0.033 DBMET01728 | ||
| 0.026 | 0.018 | 0.026 | Calcium-sensing receptor agonist | 0.025 0.021 DBMET00108 0.025 0.021 DBMET01728 | ||
| 0.061 | 0.054 | 0.061 | Bcl2 antagonist | |||
| 0.137 | 0.13 | 0.137 | DNA methylase inhibitor | |||
| 0.04 | 0.034 | 0.05 | Dopamine D2 agonist | 0.05 0.027 DBMET01213 | DBMET01213 | |
| 0.071 | 0.065 | 0.13 | Estrogen receptor alpha antagonist | 0.13 0.015 DBMET01213 | DBMET01213 | |
| 0.046 | 0.041 | 0.062 | Potassium channel (Inward rectifier) blocker | 0.062 0.022 DBMET00107 | DBMET00107 | |
| 0.05 | 0.046 | 0.069 | Beta 1 adrenoreceptor antagonist | 0.062 0.034 DBMET01213 0.069 0.027 DBMET00108 0.069 0.027 DBMET01728 | DBMET01728 | |
| 0.028 | 0.024 | 0.028 | MAP3K8 inhibitor | |||
| 0.02 | 0.017 | 0.033 | Glutaminyl-peptide cyclotransferase inhibitor | 0.033 0.005 DBMET00108 0.033 0.005 DBMET01728 | DBMET01728 | |
| 0.02 | 0.017 | 0.02 | Thymidine kinase (Herpes simplex virus 2) inhibitor | |||
| 0.015 | 0.011 | 0.017 | CXC chemokine 4 receptor agonist | 0.017 0.009 DBMET00107 | DBMET00107 | |
| 0.055 | 0.053 | 0.055 | Ryanodine receptor antagonist | 0.055 0.054 DBMET01213 | ||
| 0.03 | 0.028 | 0.03 | Vanilloid 4 antagonist | |||
| 0.025 | 0.024 | 0.025 | Thymidine kinase (Herpes simplex virus 1) inhibitor | |||
| 0.045 | 0.045 | 0.047 | Cytokine production stimulant | 0.047 0.038 DBMET00108 0.047 0.038 DBMET01728 | DBMET01728 | |
| 0.113 | 0.113 | 0.119 | Mannose-6-phosphate isomerase inhibitor | 0.119 0.102 DBMET01213 | DBMET01213 | |
| 0.165 | 0.166 | 0.178 | Nitric-oxide synthase stimulant | 0.178 0.134 DBMET00108 0.178 0.134 DBMET01728 | DBMET01728 | |
| 0.05 | 0.051 | 0.082 | Alpha 1 adrenoreceptor agonist | 0.082 0.022 DBMET00108 0.082 0.022 DBMET01728 | DBMET01728 | |
| 0.034 | 0.036 | 0.036 | Glucose-6-phosphate dehydrogenase inhibitor | 0.036 0.029 DBMET00108 0.036 0.029 DBMET01728 | DBMET01728 | |
| 0.043 | 0.047 | 0.06 | Beta 2 adrenoreceptor antagonist | 0.06 0.024 DBMET01213 0.057 0.027 DBMET00108 0.057 0.027 DBMET01728 | DBMET01213 | |
| 0.189 | 0.193 | 0.357 | Beta lactamase inhibitor | 0.357 0.113 DBMET00107 | DBMET00107 | |
| 0.122 | 0.126 | 0.152 | Dual specificity phosphatase 3 inhibitor | 0.152 0.094 DBMET01213 | DBMET01213 | |
| 0.135 | 0.14 | 0.148 | Phospholipase C inhibitor | 0.148 0.111 DBMET01213 | DBMET01213 | |
| 0.056 | 0.062 | 0.069 | Histone deacetylase inhibitor | 0.059 0.056 DBMET00107 0.069 0.041 DBMET00108 0.069 0.041 DBMET01728 | DBMET01728 | |
| 0.089 | 0.096 | 0.102 | Nav1.4 sodium channel blocker | 0.102 0.073 DBMET01213 | DBMET01213 | |
| 0.036 | 0.043 | 0.048 | 5 Hydroxytryptamine 1A agonist | 0.048 0.03 DBMET00108 0.048 0.03 DBMET01728 | DBMET01728 | |
| 0.017 | 0.024 | 0.025 | Dopamine autoreceptor agonist | 0.025 0.016 DBMET00108 0.025 0.016 DBMET01728 | DBMET01728 | |
| 0.048 | 0.055 | 0.084 | Cannabinoid CB1 receptor agonist | 0.084 0.026 DBMET00107 | DBMET00107 | |
| 0.083 | 0.092 | 0.119 | GABA C receptor rho-1 antagonist | 0.119 0.041 DBMET00108 0.119 0.041 DBMET01728 | DBMET01728 | |
| 0.042 | 0.052 | 0.046 | Dopamine beta hydroxylase inhibitor | 0.046 0.039 DBMET00108 0.046 0.039 DBMET01728 | DBMET01728 | |
| 0.038 | 0.049 | 0.087 | NMDA 2A receptor antagonist | 0.05 0.038 DBMET01213 0.087 0.017 DBMET00108 0.087 0.017 DBMET01728 | DBMET01728 | |
| 0.049 | 0.06 | 0.069 | Cannabinoid receptor agonist | 0.069 0.042 DBMET00107 | DBMET00107 | |
| 0.077 | 0.092 | 0.124 | Creatine kinase inhibitor | 0.124 0.038 DBMET01213 | DBMET01213 | |
| 0.123 | 0.137 | 0.135 | CF transmembrane conductance regulator agonist | 0.135 0.107 DBMET01213 | DBMET01213 | |
| 0.085 | 0.1 | 0.137 | Chelator | 0.137 0.041 DBMET01213 | DBMET01213 | |
| 0.068 | 0.083 | 0.1 | Viral attachment inhibitor | 0.1 0.024 DBMET00107 | DBMET00107 | |
| 0.03 | 0.046 | 0.047 | Dopamine D5 agonist | 0.047 0.02 DBMET01213 | DBMET01213 | |
| 0.051 | 0.068 | 0.061 | Neuronal nicotinic receptor antagonist | 0.061 0.054 DBMET00108 0.061 0.054 DBMET01728 | DBMET01728 | |
| 0.069 | 0.086 | 0.093 | Dual specificity tyrosine-phosphorylation regulated kinase 2 inhibitor | 0.093 0.045 DBMET01213 0.076 0.072 DBMET00108 0.076 0.072 DBMET01728 | DBMET01213 | |
| 0.014 | 0.031 | 0.019 | Estrogen-related receptor gamma agonist | 0.019 0.012 DBMET01213 | DBMET01213 | |
| 0.225 | 0.243 | 0.328 | Apoptosis agonist | 0.328 0.153 DBMET01213 | DBMET01213 | |
| 0.03 | 0.048 | 0.044 | Carbonic anhydrase IV inhibitor | 0.044 0.029 DBMET00108 0.044 0.029 DBMET01728 | DBMET01728 | |
| 0.058 | 0.077 | 0.096 | Topoisomerase II alpha inhibitor | 0.096 0.042 DBMET01213 | DBMET01213 | |
| 0.026 | 0.045 | 0.036 | Histone deacetylase 7 inhibitor | 0.036 0.026 DBMET00108 0.036 0.026 DBMET01728 | DBMET01728 | |
| 0.031 | 0.051 | 0.039 | Histone deacetylase 9 inhibitor | 0.039 0.028 DBMET00108 0.039 0.028 DBMET01728 | DBMET01728 | |
| 0.018 | 0.04 | 0.023 | ICAM 1 antagonist | 0.023 0.015 DBMET00108 0.023 0.015 DBMET01728 | DBMET01728 | |
| 0.039 | 0.068 | 0.076 | 3(or 17)beta-hydroxysteroid dehydrogenase inhibitor | 0.076 0.018 DBMET01213 | DBMET01213 | |
| 0.092 | 0.12 | 0.257 | Estrogen antagonist | 0.257 0.008 DBMET01213 | DBMET01213 | |
| 0.054 | 0.083 | 0.063 | Beta 2 adrenoreceptor agonist | 0.063 0.039 DBMET01213 0.06 0.049 DBMET00108 0.06 0.049 DBMET01728 | DBMET01213 | |
| 0.019 | 0.048 | 0.033 | HCV NS5B polymerase inhibitor | 0.033 0.019 DBMET01213 | DBMET01213 | |
| 0.154 | 0.183 | 0.277 | Peptidyltransferase inhibitor | 0.19 0.112 DBMET01213 0.195 0.106 DBMET00107 0.277 0.034 DBMET00108 0.277 0.034 DBMET01728 | DBMET01728 | |
| 0.086 | 0.115 | 0.101 | Nav1.5 sodium channel blocker | 0.101 0.083 DBMET00108 0.101 0.083 DBMET01728 | DBMET01728 | |
| 0.025 | 0.055 | 0.08 | Estradiol 17 beta-dehydrogenase inhibitor | 0.08 0.013 DBMET01213 | DBMET01213 | |
| 0.024 | 0.054 | 0.032 | RNA-directed RNA polymerase inhibitor | 0.032 0.027 DBMET01213 | DBMET01213 | |
| 0.054 | 0.085 | 0.081 | NAD(P)H dehydrogenase (quinone) inhibitor | 0.081 0.05 DBMET01213 | DBMET01213 | |
| 0.024 | 0.057 | 0.036 | Histone deacetylase class I inhibitor | 0.036 0.032 DBMET00108 0.036 0.032 DBMET01728 | DBMET01728 | |
| 0.133 | 0.166 | 0.166 | Neurotrophic factor enhancer | 0.166 0.115 DBMET01213 0.15 0.138 DBMET00108 0.15 0.138 DBMET01728 | DBMET01213 | |
| 0.028 | 0.062 | 0.046 | NMDA receptor subunit 3B antagonist | 0.046 0.028 DBMET01213 | DBMET01213 | |
| 0.019 | 0.053 | 0.076 | Estradiol 17 beta-dehydrogenase 2 inhibitor | 0.076 0.007 DBMET01213 | DBMET01213 | |
| 0.043 | 0.077 | 0.065 | Alpha 2 adrenoreceptor agonist | 0.065 0.037 DBMET00108 0.065 0.037 DBMET01728 | DBMET01728 | |
| 0.058 | 0.096 | 0.095 | Protein kinase A inhibitor | 0.095 0.048 DBMET00108 0.095 0.048 DBMET01728 | DBMET01728 | |
| 0.167 | 0.205 | 0.219 | Transcription factor NF kappa B inhibitor | 0.219 0.151 DBMET01213 0.191 0.178 DBMET00108 0.191 0.178 DBMET01728 | DBMET01213 | |
| 0.072 | 0.111 | 0.125 | Carbonic anhydrase III inhibitor | 0.125 0.041 DBMET01213 | DBMET01213 | |
| 0.078 | 0.122 | 0.107 | Cholesterol synthesis inhibitor | 0.107 0.078 DBMET01213 | DBMET01213 | |
| 0.061 | 0.105 | 0.101 | Inducible nitric-oxide synthase inhibitor | 0.101 0.036 DBMET00108 0.101 0.036 DBMET01728 | DBMET01728 | |
| 0.046 | 0.091 | 0.054 | Immunoglobulin Fc receptor antagonist | 0.054 0.042 DBMET00108 0.054 0.042 DBMET01728 | DBMET01728 | |
| 0.046 | 0.093 | 0.058 | Enoyl-[acyl-carrier-protein] reductase inhibitor | 0.058 0.048 DBMET01213 | DBMET01213 | |
| 0.043 | 0.091 | 0.061 | NMDA receptor agonist | 0.061 0.046 DBMET00108 0.061 0.046 DBMET01728 | DBMET01728 | |
| 0.138 | 0.189 | 0.227 | Streptokinase A inhibitor | 0.227 0.117 DBMET01213 | DBMET01213 | |
| 0.19 | 0.242 | 0.23 | Antibacterial | 0.23 0.196 DBMET01213 | DBMET01213 | |
| 0.009 | 0.063 | 0.024 | Estradiol 17 beta-dehydrogenase 1 inhibitor | 0.024 0.015 DBMET01213 | DBMET01213 | |
| 0.049 | 0.103 | 0.075 | Analgesic, opioid | 0.075 0.054 DBMET01213 | DBMET01213 | |
| 0.1 | 0.157 | 0.128 | Hexokinase inhibitor | 0.128 0.106 DBMET01213 | DBMET01213 | |
| 0.02 | 0.082 | 0.035 | Alpha 1d adrenoreceptor agonist | 0.035 0.032 DBMET00108 0.035 0.032 DBMET01728 | DBMET01728 | |
| 0.123 | 0.187 | 0.15 | Neurotensin receptor agonist | 0.15 0.101 DBMET00108 0.15 0.101 DBMET01728 | DBMET01728 | |
| 0.037 | 0.102 | 0.064 | Lipase inhibitor | 0.064 0.06 DBMET00108 0.064 0.06 DBMET01728 | DBMET01728 | |
| 0.07 | 0.139 | 0.129 | Histone deacetylase class III inhibitor | 0.129 0.062 DBMET00108 0.129 0.062 DBMET01728 | DBMET01728 | |
| 0.115 | 0.184 | 0.223 | Dyrk kinase inhibitor | 0.223 0.086 DBMET01213 | DBMET01213 | |
| 0.07 | 0.142 | 0.091 | Beta glucuronidase inhibitor | 0.091 0.087 DBMET01213 | DBMET01213 | |
| 0.073 | 0.149 | 0.119 | Bone formation stimulant | 0.119 0.086 DBMET01213 | DBMET01213 | |
| 0.051 | 0.128 | 0.081 | Carbonic anhydrase VI inhibitor | 0.081 0.056 DBMET01213 | DBMET01213 | |
| 0.024 | 0.101 | 0.07 | CC chemokine 5 receptor antagonist | 0.07 0.018 DBMET00107 | DBMET00107 | |
| 0.033 | 0.114 | 0.073 | Carbonic anhydrase stimulant | 0.073 0.029 DBMET00108 0.073 0.029 DBMET01728 | DBMET01728 | |
| 0.108 | 0.191 | 0.219 | Dual specificity tyrosine-phosphorylation regulated kinase 1A inhibitor | 0.219 0.082 DBMET01213 | DBMET01213 | |
| 0.081 | 0.164 | 0.169 | Histone deacetylase SIRT1 inhibitor | 0.169 0.047 DBMET00108 0.169 0.047 DBMET01728 | DBMET01728 | |
| 0.093 | 0.183 | 0.128 | Sphingosine 1-phosphate receptor 2 antagonist | 0.128 0.078 DBMET00107 | DBMET00107 | |
| 0.08 | 0.171 | 0.128 | Peroxidase inhibitor | 0.128 0.092 DBMET01213 | DBMET01213 | |
| 0.114 | 0.211 | 0.324 | Tumour necrosis factor alpha release inhibitor | 0.324 0.045 DBMET00107 | DBMET00107 | |
| 0.005 | 0.102 | 0.093 | Estrogen receptor alpha agonist | 0.093 0.009 DBMET01213 | DBMET01213 | |
| 0.018 | 0.116 | 0.038 | Estrogen-related receptor beta antagonist | 0.038 0.013 DBMET01213 | DBMET01213 | |
| 0.045 | 0.143 | 0.078 | Adrenaline agonist | 0.078 0.06 DBMET00108 0.078 0.06 DBMET01728 | DBMET01728 | |
| 0.077 | 0.183 | 0.316 | Interleukin 1 antagonist | 0.316 0.01 DBMET00107 | DBMET00107 | |
| 0.058 | 0.164 | 0.217 | Estrogen receptor beta antagonist | 0.217 0.008 DBMET01213 | DBMET01213 | |
| 0.041 | 0.153 | 0.076 | NMDA receptor antagonist | 0.076 0.07 DBMET00107 | DBMET00107 | |
| 0.023 | 0.159 | 0.073 | H+/K+-transporting ATPase inhibitor | 0.073 0.015 DBMET00107 | DBMET00107 | |
| 0.11 | 0.246 | 0.159 | Catenin beta inhibitor | 0.159 0.086 DBMET01213 | DBMET01213 | |
| 0.009 | 0.147 | 0.114 | Estrogen agonist | 0.114 0.015 DBMET01213 | DBMET01213 | |
| 0.131 | 0.288 | 0.221 | Alpha-glucosidase inhibitor | 0.221 0.205 DBMET01213 | DBMET01213 | |
| 0.057 | 0.235 | 0.097 | Glutamate (mGluR7) agonist | 0.097 0.066 DBMET00108 0.097 0.066 DBMET01728 | DBMET01728 | |
| 0.1 | 0.287 | 0.201 | Lipoxygenase inhibitor | 0.201 0.139 DBMET01213 | DBMET01213 | |
| 0.022 | 0.217 | 0.131 | Leukotriene synthesis inhibitor | 0.131 0.013 DBMET00107 | DBMET00107 | |
| 0.053 | 0.249 | 0.191 | Toll-Like receptor 3 antagonist | 0.191 0.007 DBMET00108 0.191 0.007 DBMET01728 | DBMET01728 | |
| 0.075 | 0.29 | 0.229 | Free radical scavenger | 0.229 0.078 DBMET01213 | DBMET01213 | |
| 0.008 | 0.232 | 0.115 | Beta tubulin antagonist | 0.115 0.019 DBMET00107 | DBMET00107 | |
| 0.004 | 0.236 | 0.068 | Estrogen receptor beta agonist | 0.068 0.016 DBMET01213 | DBMET01213 | |
| 0.109 | 0.402 | 0.252 | Analgesic | 0.252 0.181 DBMET00108 0.252 0.181 DBMET01728 | DBMET01728 | |
| 0.056 | 0.368 | 0.137 | Interleukin 6 antagonist | 0.137 0.11 DBMET00107 | DBMET00107 | |
| 0.057 | 0.391 | 0.212 | Antioxidant | 0.212 0.106 DBMET01213 | DBMET01213 | |
| 0.043 | 0.378 | 0.194 | Interleukin antagonist | 0.194 0.087 DBMET00107 | DBMET00107 | |
| 0.12 | 0.511 | 0.526 | Calcium channel L-type activator | 0.253 0.202 DBMET01213 0.526 0.019 DBMET00108 0.526 0.019 DBMET01728 | DBMET01728 | |
| 0.052 | 0.627 | 0.296 | Sodium/bile acid cotransporter inhibitor | 0.296 0.083 DBMET01213 | DBMET01213 | |
| 0.037 | 0.615 | 0.12 | NOS3 expression enhancer | 0.12 0.116 DBMET01213 | DBMET01213 | |
| 0.022 | 0.668 | 0.239 | Interleukin 1b antagonist | 0.239 0.013 DBMET00107 | DBMET00107 | Ext | Pa | Pi | Pmax | Activity | Other Results | ID Pa_max |